AGONISTAS DE GLP-1 NA ONCOLOGIA: ONDE ESTAMOS?

Read full text Summarise with VIRAT
Authors: Ana Clara Fernandes Cassimiro, Camila Godoy Sabatini, Giovanna Pereira Lopes, Yuri Bonicelli Crempe
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Obesity and diabetes mellitus are associated with metabolic and inflammatory alterations that contribute to increased risk and progression of various neoplasms, representing a significant challenge in contemporary oncological care. In this context, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as effective therapies for the management of type 2 diabetes and obesity, with well-established cardiometabolic benefits. Given the growing use of these agents and the increasing survival of cancer patients with metabolic comorbidities, this study aimed to evaluate, based on recent scientific literature, the effects of GLP-1 receptor agonists in the oncological setting, considering potential benefits, risks, and clinical implications. This is a systematic review of the literature conducted using the PubMed database, including studies published over the past five years that addressed the relationship between GLP-1 receptor agonists and oncological outcomes. The results suggest that the use of GLP-1 receptor agonists is associated with potential protective effects in certain types of cancer, particularly those related to obesity and insulin resistance, likely mediated by indirect mechanisms such as weight loss, improved insulin sensitivity, and reduced systemic inflammation. Meta-analyses of randomized controlled trials did not demonstrate a significant increase in the risk of gastrointestinal cancers, including pancreatic and hepatic neoplasms. However, heterogeneous findings persist regarding the risk of thyroid cancer, requiring cautious interpretation and ongoing clinical surveillance. It is concluded that GLP-1 receptor agonists represent a promising strategy in the integrated care of oncological patients with obesity and diabetes, although prospective and long-term studies are needed to establish their oncological safety and to guide evidence-based clinical practice.

Fields of Study & Subjects

Metabolism Diabetes and Cancer Diabetes Treatment and Management Cancer Risks and Factors

Publication details

Pages
190–197
Publication date
24 March 2026
Language
EN
Document type
Book chapter